Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pain 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1Breast Diseases 1Agnosia 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 29Papillomavirus Vaccines 22Vaccines 11Human Papillomavirus Recombinant Vaccine nonavalent 11Radiotherapy, Intensity-Modulated 7Human Papillomavirus DNA Tests 7Colposcopy 7Cisplatin 7Educational Status 6Carboplatin 6Blood Specimen Collection 6Vaccines, Synthetic 5Specimen Handling 5Early Intervention, Educational 5Vaginal Smears 4Methods 4Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Surveys and Questionnaires 3Patient Navigation 3Paclitaxel 3Imiquimod 3Hepatitis A Vaccines 3Cyclophosphamide 3halofantrine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Papillomavirus Infections × Codeine × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡